Envoy Medical, Inc. (COCH) intrinsic value & 10-year financials
Envoy Medical, Inc. (COCH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 0.6% a year to $241.0K, with an average return on invested capital of 135.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.67
- Market cap
- $15.5M
- Revenue (FY2025)
- $241.0K
- Revenue growth (6-yr CAGR)
- 0.6%
- ROIC (10-yr avg)
- 135.4%
- Free cash flow (FY2025)
- -$18.4M
COCH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $241.0K | -$23.8M | -$1.23 | -$18.4M | -9240.7% | 153.3% |
| FY2024 | $225.0K | -$20.8M | -$1.49 | -$18.9M | -8558.2% | 201.9% |
| FY2023 | $316.0K | -$29.9M | -$2.38 | -$17.8M | -5813.6% | 304.0% |
| FY2022 | $237.0K | $19.2M | -$1.57 | -$2.9M | -2062.5% | 16.6% |
| FY2021 | — | -$251.6K | — | — | — | 1.4% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Envoy Medical, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Envoy Medical, Inc. has historically struggled to out-earn its cost of capital, averaging just 4.9% ROIC.
Envoy Medical, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Envoy Medical, Inc. is modeled at 0.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-10.21 per share.